Ketamine Therapy in District of Columbia

Ketamine therapy in the District of Columbia is regulated primarily through federal Drug Enforcement Administration (DEA) guidelines, as ketamine remains a Schedule III controlled substance under the federal Controlled Substances Act. Providers in DC must hold valid DEA registration to prescribe, administer, or dispense ketamine, and all clinics must comply with District of Columbia Board of Medicine standards for licensed practitioners. The DC Department of Health (DC Health) oversees healthcare facility licensing and ensures that clinics operating within the District meet applicable safety, staffing, and administrative requirements.

Physicians, nurse practitioners, and other qualified providers administering ketamine infusions or esketamine (Spravato) must operate within their defined scope of practice under DC law. Esketamine (Spravato), the FDA-approved intranasal formulation for treatment-resistant depression, must be administered under a certified Risk Evaluation and Mitigation Strategy (REMS) program, which requires patients to be monitored on-site for a minimum of two hours following each dose. Off-label intravenous ketamine infusions, while widely practiced, are not specifically regulated by a separate DC statute and therefore fall under general medical practice standards and professional board oversight.

Clinics in the District of Columbia are expected to adhere to the following general compliance standards:

• Valid DEA Schedule III controlled substance registration for all prescribing providers
• Active licensure with the DC Board of Medicine or relevant professional licensing board
• Compliance with DC Health facility and ambulatory care center regulations
• Proper controlled substance storage, record-keeping, and disposal protocols
• Adherence to FDA REMS requirements for any esketamine administration
• Informed consent documentation and patient monitoring protocols

As the landscape of ketamine and psychedelic-assisted therapies continues to evolve, the District of Columbia has shown progressive legislative interest in expanding access to alternative mental health treatments. Patients seeking ketamine therapy in DC are encouraged to verify that their chosen provider maintains current licensure and DEA registration, and to consult directly with clinic staff regarding treatment protocols, oversight procedures, and any applicable insurance or prior authorization requirements.